SYDNEY--Australia-based pharmaceutical company CSL will expand its Illinois manufacturing facility under a previously announced $1.5 billion move to increase U.S. production. CSL, which produces ...

Genezen reports that the company became the first CDMO to license CSL’s Cytegrity™ cell line production system that was designed for the production of lentiviral vectors (LVVs). “We have significant, ...

CSL shares are tumbling again on Wednesday. Here's what it'll take for the price to take a u-turn. The post Prediction: CSL ...

Australia’s largest drugmaker CSL Ltd. is committing roughly $1.5 billion to expand its US manufacturing footprint, joining a wave of pharmaceutical giants doubling down on American production. The ...

CSL is one of three Tier 1 plasma therapy companies that benefit from an oligopoly in a highly consolidated market. All the players are vertically integrated as plasma sourcing is a key constraint in ...